RaySearch Laboratories
Market Cap
US$5.6b
Last Updated
2019/09/21 00:29 UTC
Data Sources
Company Financials +
Executive Summary
RaySearch Laboratories AB (publ) operates as a medical technology company that develops software solutions for cancer treatment in North America, Asia, Europe, and internationally.
Snowflake
Fundamentals
Excellent balance sheet with reasonable growth potential.
Risks
- RaySearch Laboratories has significant price volatility in the past 3 months.
- RaySearch Laboratories is covered by less than 3 analysts.
Similar Companies
Share Price & News
How has RaySearch Laboratories's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
0%
RSLB.F
2.5%
US Healthcare Services
-0.6%
US Market
1 Year Return
28.7%
RSLB.F
10.3%
US Healthcare Services
0.6%
US Market
RSLB.F outperformed the Healthcare Services industry which returned 8.7% over the past year.
RSLB.F outperformed the Market in United States of America which returned 1.1% over the past year.
Share holder returns
| RSLB.F | Industry | Market | |
|---|---|---|---|
| 7 Day | 0% | 2.5% | -0.6% |
| 30 Day | 4.3% | -2.9% | 2.2% |
| 90 Day | n/a | -4.1% | 1.1% |
| 1 Year | 28.7%28.7% | 10.4%10.3% | 2.9%0.6% |
| 3 Year | -1.3%-1.3% | 51.9%51.6% | 44.6%35.2% |
| 5 Year | 225.0%225.0% | 52.0%51.1% | 61.9%44.2% |
Price Volatility Vs. Market
How volatile is RaySearch Laboratories's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is RaySearch Laboratories undervalued based on future cash flows and its price relative to the stock market?
65.89x
Price to Earnings (PE) ratio
Intrinsic Value Based on Future Cash Flows
RaySearch Laboratories's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
RaySearch Laboratories's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
Price Based on Earnings
RaySearch Laboratories is overvalued based on earnings compared to the US Healthcare Services industry average.
RaySearch Laboratories is overvalued based on earnings compared to the United States of America market.
Price Based on Expected Growth
RaySearch Laboratories is poor value based on expected growth next year.
Price Based on Value of Assets
RaySearch Laboratories is overvalued based on assets compared to the US Healthcare Services industry average.
Next Steps
Future Growth
How is RaySearch Laboratories expected to perform in the next 1 to 3 years based on estimates from 2 analysts?
33.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
RaySearch Laboratories's revenue is expected to grow by 17.3% yearly, however this is not considered high growth (20% yearly).
RaySearch Laboratories's earnings are expected to grow significantly at over 20% yearly.
RaySearch Laboratories's revenue growth is expected to exceed the United States of America market average.
RaySearch Laboratories's earnings growth is expected to exceed the United States of America market average.
RaySearch Laboratories's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
RaySearch Laboratories is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
Next Steps
Past Performance
How has RaySearch Laboratories performed over the past 5 years?
15.1%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
RaySearch Laboratories's year on year earnings growth rate has been positive over the past 5 years.
RaySearch Laboratories's 1-year earnings growth is negative, it can't be compared to the 5-year average.
RaySearch Laboratories's 1-year earnings growth is negative, it can't be compared to the US Healthcare Services industry average.
Return on Equity
RaySearch Laboratories has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
Return on Assets
RaySearch Laboratories used its assets more efficiently than the US Healthcare Services industry average last year based on Return on Assets.
Return on Capital Employed
RaySearch Laboratories's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Next Steps
Financial Health
How is RaySearch Laboratories's financial position?
Financial Position Analysis
RaySearch Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
RaySearch Laboratories's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
RaySearch Laboratories's level of debt (1.8%) compared to net worth is satisfactory (less than 40%).
Unable to establish if RaySearch Laboratories's debt level has increased without past 5-year debt data.
Debt is well covered by operating cash flow (2394.9%, greater than 20% of total debt).
Interest payments on debt are well covered by earnings (EBIT is 20.2x coverage).
Balance Sheet
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 44.8x debt.
Next Steps
Dividend
What is RaySearch Laboratories's current dividend yield, its reliability and sustainability?
0.39%
Expected Dividend Yield
Dividend Yield and Payments Analysis
Unable to evaluate RaySearch Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate RaySearch Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as RaySearch Laboratories has not reported any payouts.
Unable to verify if RaySearch Laboratories's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as RaySearch Laboratories has not reported any payouts.
Future Payout to Shareholders
No need to calculate the sustainability of RaySearch Laboratories's dividends in 3 years as they are not expected to pay a notable one for United States of America.
Next Steps
Management
What is the CEO of RaySearch Laboratories's salary, the management and board of directors tenure and is there insider trading?
4.0yrs
Average management tenure
CEO
Johan Löf (50yo)
19.7yrs
Tenure
kr9,214,000
Compensation
Dr. Johan Löf has been the Chief Executive Officer and President of Raysearch Laboratories AB (Publ) since 2000. Dr. Löf serves as the Chief Executive Officer of RaySearch Medical AB. Dr. Löf has been a Di ...
CEO Compensation Analysis
Johan's remuneration is lower than average for companies of similar size in United States of America.
Johan's compensation has been consistent with company performance over the past year, both up more than 20%.
Management Age and Tenure
4.0yrs
Average Tenure
46yo
Average Age
The tenure for the RaySearch Laboratories management team is about average.
Board Age and Tenure
15.3yrs
Average Tenure
58yo
Average Age
The average tenure for the RaySearch Laboratories board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Insider Trading
RaySearch Laboratories individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Shares | 7,299 |
| Max Price | kr16.76 |
| Entity | Individual |
| Role | Chief Executive Officer Founder |
| Shares | 200,000 |
| Max Price | kr18.96 |
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 5,000 |
| Max Price | kr19.25 |
| Entity | Individual |
| Role | Chief Executive Officer Founder |
| Shares | 5,370 |
| Max Price | kr10.96 |
Ownership Breakdown
Management Team
Johan Löf (50yo)
Founder
- Tenure: 19.7yrs
- Compensation: kr9.21m
Petra Jansson (46yo)
General Counsel
- Tenure: 2.2yrs
Marc Mlyn
President of Raysearch Americas Inc
- Tenure: 0yrs
Björn Hårdemark (42yo)
Deputy Chief Executive Officer
- Tenure: 4yrs
Peter Thysell (49yo)
Chief Financial Officer
- Tenure: 4.2yrs
Peter Kemlin (45yo)
Director of Sales & Marketing
- Tenure: 0yrs
Kjell Eriksson (46yo)
Chief Science Officer
- Tenure: 4yrs
Board Members
Hans Wigzell (81yo)
Director
- Tenure: 15.3yrs
- Compensation: kr221.00k
Johan Löf (50yo)
Founder
- Tenure: 19.7yrs
- Compensation: kr9.21m
Carl Bergendal (74yo)
Director
- Tenure: 19.7yrs
- Compensation: kr480.00k
Lars Wollung (58yo)
Chairman of the Board
- Tenure: 0.3yrs
Radhe Mohan
Member of Scientific Advisory Board
- Tenure: 16.7yrs
Anders Forsgren
Member of Scientific Advisory Board
- Tenure: 0yrs
Anders Brahme (75yo)
Member of Scientific Advisory Board
- Tenure: 0yrs
David Jaffray
Member of Scientific Advisory Board
- Tenure: 0yrs
Johanna Öberg (44yo)
Director
- Tenure: 2.3yrs
- Compensation: kr152.00k
Britta Wallgren (56yo)
Director
- Tenure: 1.3yrs
Company Information
RaySearch Laboratories AB (publ)'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: RaySearch Laboratories AB (publ)
- Ticker: RSLB.F
- Exchange: OTCPK
- Founded: 2000
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: kr5.629b
- Listing Market Cap: kr579.050m
- Shares outstanding: 34.28m
- Website: https://www.raysearchlabs.com
Number of Employees
Location
- RaySearch Laboratories AB (publ)
- Sveavägen 44
- Stockholm
- Stockholm County
- 111 34
- Sweden
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| RAY B | OM (OMX Nordic Exchange Stockholm) | Yes | Class B Shares | SE | SEK | Jun 2003 |
| 0GRZ | LSE (London Stock Exchange) | Yes | Class B Shares | GB | SEK | Jun 2003 |
| RSLB.F | OTCPK (Pink Sheets LLC) | Yes | Class B Shares | US | USD | Jun 2003 |
| 27R | DB (Deutsche Boerse AG) | Yes | Class B Shares | DE | EUR | Jun 2003 |
| RAYBS | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Class B Shares | GB | SEK | Jun 2003 |
Biography
RaySearch Laboratories AB (publ) operates as a medical technology company that develops software solutions for cancer treatment in North America, Asia, Europe, and internationally. It develops and markets ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/21 00:29 |
| End of Day Share Price | 2019/08/27 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.